Hospital-specific calculation of heparin-induced thrombocytopenia costs: a review (Artikel)

Aus Kompetenzportal
Wechseln zu: Navigation, Suche
Hospital-specific calculation of heparin-induced thrombocytopenia costs: a review (Artikel)
Autor Thomas Wilke, Andreas Greinacher
In: Journal of Laboratory Medicine
Ausgabe 35 (1)
ISBN/ISSN: 1439-0477
Erscheinungsjahr 2010
Jahrgang Juli 2010
Seitenzahl 35-43
Hyperlink http://www.degruyter.com/view/j/labm.2011.35.issue-1/jlm.2010.020/jlm.2010.020.xml
Review

Costs for heparin-induced thrombocytopenia (HIT) should be considered for any assessment of the cost-effectiveness of a certain strategy of thrombosis prophylaxis in a hospital. Five recent studies analyzed the cost of HIT as primary outcome. These studies reported widely differing estimates for the costs of a HIT case, which might be largely related to the different methodological approaches. The most plausible HIT cost estimates range between €9,000 and €15,000 per case for European hospitals and US$30,000–45,000 per case for hospitals in the United States. The approximate threefold cost difference between Europe and the US is to some extent caused by the very different costs for certain interventions and treatments, i.e., they are dependent on the economic environment of the hospitals analyzed. Based on the assumption that clinical management of acute HIT does not differ substantially between different medical systems, we recently developed the HIT cost calculator based on detailed analysis of additional resources required owing to the presence of HIT in 128 patients with clinical HIT. This tool offers interested hospitals a very transparent method to calculate their own HIT-related costs.